Patient characteristics at baseline (ISS stage and FISH studies) and near day 100 post-ASCT (serum M spike, sFLC ratio, CR status, maintenance therapy)
| . | Entire cohort, n = 229 . | Day 100 PET+, n = 149 . | Day 100 PET−, n = 80 . | P . |
|---|---|---|---|---|
| Serum M spike at day 100, median (range), g/dL | 0.2 (0-2.7) | 0 (0-2.7) | 0.4 (0-2.6) | |
| sFLC ratio at day 100, median (range) | 1.4 (0-1444) | 1.36 (0-1445) | 1.66 (0.02-497) | |
| ISS stage III* | 43/156 (28) | 28/156 (18) | 15/156 (9.6) | .81 |
| High-risk FISH* | 42/170 (24.7) | 29/170 (17) | 13/170 (7.6) | .5 |
| CR at day 100* | 51/221 (23) | 30/221 (13.6) | 21/221 (9.5) | .37 |
| Maintenance therapy* | 62/220 (28) | 37/220 (17) | 25/220 (11) | .39 |
| . | Entire cohort, n = 229 . | Day 100 PET+, n = 149 . | Day 100 PET−, n = 80 . | P . |
|---|---|---|---|---|
| Serum M spike at day 100, median (range), g/dL | 0.2 (0-2.7) | 0 (0-2.7) | 0.4 (0-2.6) | |
| sFLC ratio at day 100, median (range) | 1.4 (0-1444) | 1.36 (0-1445) | 1.66 (0.02-497) | |
| ISS stage III* | 43/156 (28) | 28/156 (18) | 15/156 (9.6) | .81 |
| High-risk FISH* | 42/170 (24.7) | 29/170 (17) | 13/170 (7.6) | .5 |
| CR at day 100* | 51/221 (23) | 30/221 (13.6) | 21/221 (9.5) | .37 |
| Maintenance therapy* | 62/220 (28) | 37/220 (17) | 25/220 (11) | .39 |
FISH, fluorescence in situ hybridization; ISS, International Staging System; sFLC, serum free light chain.
Reported as number of patients among the entire cohort with available prognostic data per variable (percentage).